Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glucagon Clear all
Recruiting Phase 4 Interventional

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

NCT07111494
View directory record Official record
Conditions
Psoriatic Arthritis (PsA)
Interventions
GLP-1 agonists, Nutrition Counseling
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Not applicable Interventional Results available

Glutamine and Insulin Sensitivity in Type I Diabetes

NCT01467063
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Glutamine, Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 24, 2026, 1:14 PM EDT
Enrolling by invitation No phase listed Observational

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

NCT01511393
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
6,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2039
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

DPP4 Inhibition & Beta Cell Function

NCT02683187
View directory record Official record
Conditions
Healthy
Interventions
Active Comparator: Sitagliptin, Placebo Comparator - No Sitagliptin
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
35 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

NCT02465515
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Albiglutide 30 mg, Albiglutide 50 mg, Albiglutide matching placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
9,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
146
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 24, 2026, 1:14 PM EDT
Terminated Not applicable Interventional

Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation

NCT06273163
View directory record Official record
Conditions
Obesity
Interventions
Medically tailored meals, Noom®, Usual care
Other · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
View directory record Official record
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 24, 2026, 1:14 PM EDT
Recruiting Not applicable Interventional

Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

NCT07091500
View directory record Official record
Conditions
Obesity, Skeletal Muscle, Brain Connectivity
Interventions
Exercise training, Semaglutide, Therapy Cessation
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 24, 2026, 1:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

NCT06424106
View directory record Official record
Conditions
PreDiabetes
Interventions
Glucagon, Glucose
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Not applicable Interventional Results available

Physiologic Response to Glucagon at Varying Insulin Levels

NCT01483651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon, Insulin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 24, 2026, 1:14 PM EDT
Recruiting Not applicable Interventional

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

NCT06734312
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
Interventions
Gastric Fundal Mucosal Ablation (GFMA)
Device
Lead sponsor
Dr. Christopher McGowan
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Short Bowel Syndrome and Teduglutide Versus Placebo

NCT02099084
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

NCT01919684
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LGD-6972, Placebo (Captisol®)
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 24, 2026, 1:14 PM EDT
Not listed Not applicable Interventional

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

NCT05973799
View directory record Official record
Conditions
Hypoglycemia, Type1diabetes
Interventions
Fasting, Feeding
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

NCT02592421
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 24, 2026, 1:14 PM EDT
Suspended Phase 4 Interventional

Effects of DPP-4 Inhibition on Triglycerides

NCT01527747
View directory record Official record
Conditions
Type 2 Diabetes, Hypertriglyceridemia
Interventions
Saxagliptin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 24, 2026, 1:14 PM EDT
Withdrawn Not applicable Interventional

Sitagliptin in Type I Diabetic Patients

NCT01741103
View directory record Official record
Conditions
Diabetes Type I
Interventions
sitagliptin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

NCT02081001
View directory record Official record
Conditions
Hypoglycemia
Interventions
Novo Nordisk GlucaGen®, G-Pump™ (glucagon infusion)
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Not applicable Interventional Results available

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

NCT03258853
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

NCT01234649
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 24, 2026, 1:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index

NCT02663661
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Metabolic Challenge Admission, CGM home test
Procedure · Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 45 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 24, 2026, 1:14 PM EDT
Terminated Phase 2 Interventional Results available

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

NCT03490942
View directory record Official record
Conditions
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Interventions
Glucagon, Placebo
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
21 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 24, 2026, 1:14 PM EDT